Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7 - 2Illustrations Gained from a Crosscountry Excursion
- 3We may have one thing in common with jellyfish, new research finds
- 4DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- 5AfD faction in western Germany ousts councilman for firebrand speech
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 2024 Watch Gathering: The Best Watches of the Year
- German foreign minister heads to China to talk rare-earth exports
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market
- Air superiority and long-range strikes: what China's war games say about how it might assault Taiwan
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
